Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

755
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Angina IV: Management01:26

Angina IV: Management

347
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
347
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

506
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
506

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Collaborative neurocardiology board meetings for decision-making in stroke care: a real-world experience.

Neurological research and practice·2026
Same author

Editorial: Current proceedings in magnetocardiology-past, present, future.

Frontiers in cardiovascular medicine·2024
Same author

Magnetocardiography at rest predicts cardiac death in patients with acute chest pain.

Frontiers in cardiovascular medicine·2023
Same author

Medical graphics to improve patient understanding and anxiety in elderly and cognitively impaired patients scheduled for transcatheter aortic valve implantation (TAVI).

Clinical research in cardiology : official journal of the German Cardiac Society·2023
Same author

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.

Clinical research in cardiology : official journal of the German Cardiac Society·2023

Related Experiment Video

Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

[Dyslipidemias : Diagnostics and management].

D Sinning1, U Landmesser2,3,4

  • 1Klinik für Kardiologie, Charité Centrum für Herz‑, Kreislauf- und Gefäßmedizin, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland.

Herz
|August 10, 2017
PubMed
Summary
This summary is machine-generated.

Lowering low-density lipoprotein (LDL) cholesterol is key for managing lipid disorders and preventing atherosclerotic cardiovascular disease (ACVD). Statins, ezetimibe, and PCSK9 inhibitors effectively reduce cardiovascular events in high-risk patients.

Keywords:
Cardiovascular riskHDL cholesterolLDL cholesterolLipid metabolismStatins

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K

Related Experiment Videos

Last Updated: Feb 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.8K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.6K

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Disorders of lipid metabolism require risk-adapted adjustment of low-density lipoprotein (LDL) cholesterol to minimize atherosclerotic cardiovascular disease (ACVD) progression.
  • Statins are the recommended first-line treatment for dyslipidemias due to their proven efficacy in reducing cardiovascular morbidity and mortality.

Purpose of the Study:

  • To review current strategies for managing lipid metabolism disorders.
  • To highlight the role of various pharmacological interventions and lifestyle changes in cardiovascular risk reduction.

Main Methods:

  • Review of current clinical guidelines and pharmacological treatments for lipid disorders.
  • Analysis of evidence supporting the use of statins, ezetimibe, and PCSK9 inhibition.
  • Consideration of lifestyle modifications and the role of HDL cholesterol and lipoprotein(a) assessment.

Main Results:

  • LDL cholesterol remains the primary target for managing lipid metabolism disorders and preventing ACVD.
  • Statins, ezetimibe, and PCSK9 inhibitors are effective in reducing cardiovascular events in high-risk individuals.
  • Lifestyle changes can improve lipid profiles, especially for hypertriglyceridemia, but direct evidence for targeting HDL cholesterol or Lp(a) to reduce events is lacking.

Conclusions:

  • Risk-adapted LDL cholesterol management is crucial for preventing ACVD.
  • Pharmacological interventions like statins, ezetimibe, and PCSK9 inhibition are vital for high-risk patients.
  • Further research is needed to establish the efficacy of targeting HDL cholesterol and Lp(a) for cardiovascular event reduction.